Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

58451AST

Supelco

Chiral HSA HPLC Column

5 μm particle size, L × I.D. 15 cm × 4 mm

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
41115700
eCl@ss:
32110501
NACRES:
SB.52

Materiali

stainless steel column

Livello qualitativo

agenzia

suitable for USP L79

Nome Commerciale

CHIRALPAK®

Confezionamento

pkg of 1 ea

Produttore/marchio commerciale

CHIRALPAK®

Parametri

137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.

tecniche

HPLC: suitable

Lungh. × D.I.

15 cm × 4 mm

Matrice

fully porous particle

Gruppo funzionale matrice

human serum albumin phase

Dimensione particelle

5 μm

pH di lavoro

2-8

Tecnica di separazione

chiral

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)

Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.

(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.

Prodotti consigliati

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Note legali

CHIRALPAK is a registered trademark of Daicel Corp.

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.